Luye Pharma Group Ltd.
HKSE: 2186.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Dian Bo Liu
- Employees
- 5,150
- Headquarters
- Yantai, China
- IPO year
- 2014
- Market cap
- HK$10.4B
- Website
- https://www.luye.cn
Loading 2186…
Loading profile data…Frequently asked questions about 2186
What does Luye Pharma Group Ltd. (2186.HK) do?
Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various type...
Where does 2186.HK trade?
Luye Pharma Group Ltd. (2186.HK) trades on the Hong Kong Stock Exchange.
What sector is 2186.HK in?
Luye Pharma Group Ltd. (2186.HK) operates in the Healthcare sector, specifically in the Drug Manufacturers - General industry.
Who is the CEO of Luye Pharma Group Ltd.?
Dian Bo Liu is the chief executive officer of Luye Pharma Group Ltd. (2186.HK).
Where is Luye Pharma Group Ltd. headquartered?
Luye Pharma Group Ltd. is headquartered in China.
Does 2186.HK pay a dividend?
Luye Pharma Group Ltd. (2186.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 2186.HK go public?
Luye Pharma Group Ltd. (2186.HK) completed its initial public offering in 2014.